Profile data is unavailable for this security.
About the company
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
- Revenue in CHF (TTM)--
- Net income in CHF--
- Incorporated2022
- Employees23.85k
- LocationSandoz Group AGSuurstoffi 14ROTKREUZ 6343SwitzerlandCHE
- Websitehttps://www.sandoz.com/
More ▼
Mergers & acquisitions
| Acquired company | SDZ:SWX since announced | Transaction value |
|---|---|---|
| Coherus BioSciences Inc-CIMERLI Business | 16.99% | 170.00m |
Data delayed at least 15 minutes, as of Jul 03 2024 11:05 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris Inc | 13.88bn | -50.71m | 11.23bn | 38.00k | -- | 0.6204 | 4.69 | 0.8085 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Dr Reddy's Laboratories Ltd | 3.03bn | 603.74m | 11.48bn | 24.83k | 19.04 | 3.75 | 15.05 | 3.79 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 2.12bn | 415.26m | 11.70bn | 23.03k | 28.34 | 5.45 | 23.53 | 5.53 | 37.91 | 38.14 | 193.16 | 197.11 | 0.7103 | 1.82 | 4.06 | -- | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 62.16 | 19.60 | 14.33 | 1.51 | 22,696.00 | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Incyte Corp | 3.41bn | 673.81m | 11.98bn | 2.52k | 17.92 | 2.46 | 15.95 | 3.52 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Cipla Ltd | 2.79bn | 446.11m | 13.01bn | 26.62k | 29.17 | 4.50 | 23.09 | 4.66 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 849.13m | 173.18m | 13.14bn | 16.95k | 75.85 | 8.94 | 61.35 | 15.47 | 60.27 | 60.27 | 295.54 | 511.21 | 0.5246 | 1.01 | 3.97 | -- | 10.70 | 16.55 | 11.62 | 18.22 | 60.11 | 57.95 | 20.40 | 26.38 | 5.08 | -- | 0.0002 | 34.33 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Royalty Pharma plc | 2.02bn | 722.09m | 13.98bn | 89.00 | 14.52 | 1.80 | 12.98 | 6.91 | 1.78 | 1.78 | 3.73 | 14.41 | 0.1348 | -- | 73.80 | 25,152,370.00 | 7.15 | 9.57 | 9.60 | 12.42 | -- | -- | 53.01 | 67.80 | -- | -- | 0.3836 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Sandoz Group AG | -100.00bn | -100.00bn | 14.02bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Biomarin Pharmaceutical Inc | 2.23bn | 185.71m | 14.11bn | 3.40k | 77.83 | 3.08 | 50.24 | 6.32 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7116 | 3.54 | 0.8079 | 79.22 | 76.30 | 8.31 | 2.05 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 1.32bn | 373.20m | 15.51bn | 2.79k | 41.56 | 8.71 | -- | 11.77 | 4.98 | 4.98 | 17.57 | 23.76 | 0.6354 | 1.74 | 13.24 | 3,800,528.00 | 18.30 | 18.82 | 22.61 | 23.91 | 45.77 | 46.55 | 28.81 | 27.98 | 4.02 | -- | 0.0898 | 36.49 | 15.69 | 16.11 | 13.15 | 19.60 | 13.83 | 31.06 |
| Astellas Pharma Inc | 8.98bn | 95.42m | 16.09bn | 14.75k | 168.98 | 1.78 | 16.43 | 1.79 | 9.40 | 9.40 | 892.49 | 890.07 | 0.5322 | 1.38 | 3.33 | 108,694,000.00 | 0.5657 | 4.59 | 0.8492 | 6.61 | 81.76 | 80.53 | 1.06 | 7.98 | 0.7358 | 22.28 | 0.3866 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Teva Pharmaceutical Industries Ltd | 14.46bn | -445.36m | 16.69bn | 35.00k | -- | 2.54 | 56.48 | 1.15 | -1.66 | -1.66 | 53.61 | 24.20 | 0.3712 | 1.96 | 4.64 | 1,722,027.00 | -1.84 | -3.14 | -2.60 | -4.29 | 50.62 | 48.14 | -4.96 | -9.87 | 0.6053 | 4.36 | 0.7226 | -- | 6.17 | -3.42 | 77.15 | -- | -4.17 | -- |
Data as of Jul 03 2024. Currency figures normalised to Sandoz Group AG's reporting currency: Swiss Franc CHF
17.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Jun 2024 | 16.08m | 3.73% |
| UBS Asset Management Switzerland AGas of 04 Jun 2024 | 12.36m | 2.87% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 10.49m | 2.43% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Apr 2024 | 8.05m | 1.87% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 7.00m | 1.63% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 5.35m | 1.24% |
| J.O. Hambro Capital Management Ltd.as of 31 Dec 2023 | 4.31m | 1.00% |
| Eleva Capital LLPas of 31 Dec 2023 | 4.05m | 0.94% |
| Artisan Partners LPas of 31 Mar 2024 | 3.98m | 0.92% |
| Vontobel Asset Management AGas of 31 May 2024 | 3.85m | 0.89% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
